The Fibro-Targets project is a multi-disciplinary program involving 11 partners ambitioning "the identification, characterization and validation of in vitro and in vivo models of novel therapeutically relevant targets" for myocardial interstitial fibrosis (MIF) in heart failure (HF).
The project intents to analyze novel fibrosis-related targets to develop new strategies for the prevention and treatment of adverse cardiac remodeling involved in the transition to and the progression of HF. Preliminary work by members of the consortium identified a number of specific extracellular and intracellular targets whose involvement in MIF will be examined and targeted by specific therapies.
The specific aims of the Fibro-Targets are:
- To provide evidence on the mechanisms of action of novel targets
- To develop new anti-fibrotic strategies
- To approach a clinical scenario of theses targets for HF therapy.
The Medical University of Vienna is responsible for the large animal model of myocardial infarction-related cardiac fibrosis, and for validation of the newly developed antifibrotic drug treatment. These translational experiments will address the feasibility, safety and efficacy of the selected substances using clinical settings under similar conditions as used in humans.
MedUni Vienna Researcher
The Medical University of Vienna is project partner under the leadership of Prof.in Dr.in Mariann Gyöngyösi, Department of Medicine II, Department of Cardiology
Project Coordinator: Prof. Dr. Faiez Zannad
, Hôpital Brabois
11 project partners
|Topic||FP7-HEALTH-2013-INNOVATION-1: Discovery research to reveal novel targets for cardiovascular disease treatment|
|Funding volume, total||6.000.000 EUR|
|Funding volume, Medical University of Vienna||680.000 EUR|